EP0880511A4 - Antagonistes du recepteur integrine - Google Patents

Antagonistes du recepteur integrine

Info

Publication number
EP0880511A4
EP0880511A4 EP97902931A EP97902931A EP0880511A4 EP 0880511 A4 EP0880511 A4 EP 0880511A4 EP 97902931 A EP97902931 A EP 97902931A EP 97902931 A EP97902931 A EP 97902931A EP 0880511 A4 EP0880511 A4 EP 0880511A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
integrin receptor
integrin
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97902931A
Other languages
German (de)
English (en)
Other versions
EP0880511A1 (fr
Inventor
George D Hartman
James J Perkins
Mark E Duggan
Cecilia A Hunt
Amy E Krause
Nathan C Ihle
Ben Askew
John Hutchinson
Karen Brashear
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603373.3A external-priority patent/GB9603373D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0880511A1 publication Critical patent/EP0880511A1/fr
Publication of EP0880511A4 publication Critical patent/EP0880511A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97902931A 1996-01-16 1997-01-13 Antagonistes du recepteur integrine Withdrawn EP0880511A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US996596P 1996-01-16 1996-01-16
US9965P 1996-01-16
GBGB9603373.3A GB9603373D0 (en) 1996-02-16 1996-02-16 Integrin receptor antagonists
GB9603373 1996-02-16
PCT/US1997/000572 WO1997026250A1 (fr) 1996-01-16 1997-01-13 Antagonistes du recepteur integrine

Publications (2)

Publication Number Publication Date
EP0880511A1 EP0880511A1 (fr) 1998-12-02
EP0880511A4 true EP0880511A4 (fr) 1999-06-16

Family

ID=26308745

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97902931A Withdrawn EP0880511A4 (fr) 1996-01-16 1997-01-13 Antagonistes du recepteur integrine

Country Status (5)

Country Link
EP (1) EP0880511A4 (fr)
JP (1) JP2000516197A (fr)
AU (1) AU713676B2 (fr)
CA (1) CA2242877A1 (fr)
WO (1) WO1997026250A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981546A (en) * 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
US6211184B1 (en) 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
US5952341A (en) * 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
GB2327609A (en) * 1997-07-23 1999-02-03 Merck & Co Inc A method for eliciting an avß5 or dual avß3/avß5 antagonizing effect
US6294549B1 (en) 1997-07-23 2001-09-25 Merck & Co., Inc. Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect
KR20010033248A (ko) * 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6001855A (en) * 1998-01-02 1999-12-14 Hoffman-La Roche Inc. Thiazole derivatives
CA2333927A1 (fr) 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Antagonistes de l'integrine
ES2381591T3 (es) 1998-04-09 2012-05-29 Meiji Seika Pharma Co., Ltd. Derivados de aminopiperidina como antagonistas de integrina alfa v beta 3
DE19831710A1 (de) * 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
EP1153014B1 (fr) 1999-02-20 2004-09-22 MERCK PATENT GmbH Derives de la beta-alanine
AU5011300A (en) 1999-05-14 2000-12-05 Combichem, Inc. Cyclic amine derivatives and their uses
WO2000072801A2 (fr) 1999-06-02 2000-12-07 Merck & Co., Inc. Antagonistes du recepteur de l'alpha v integrine
EP1209152A4 (fr) 1999-08-05 2003-03-12 Meiji Seika Kaisha Derives d'acide omega-amino-alpha-hydroxycarboxylique possedant un antagonisme alpha v beta 3 d'integrine
DK1302461T3 (da) * 2000-05-31 2008-01-28 Santen Pharmaceutical Co Ltd TNF-alfa-produktionsinhibitorer
DE10041423A1 (de) * 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
EP1446418B1 (fr) * 2001-10-22 2012-05-23 The Scripps Research Institute Composes de ciblage de l'integrine
US7317019B2 (en) 2003-08-21 2008-01-08 Bristol Myers Squibb Co. N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény
US20180244648A1 (en) 2017-02-28 2018-08-30 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
CR20210109A (es) 2018-08-29 2021-06-24 Morphic Therapeutic Inc INHIBICIÓN DE LA INTEGRINA av ß6

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0384362A2 (fr) * 1989-02-23 1990-08-29 F. Hoffmann-La Roche Ag Dérivés de la glycine
WO1991005562A1 (fr) * 1989-10-10 1991-05-02 Rorer International (Holdings), Inc. Peptides et pseudopeptides anti-thrombotiques
EP0512831A1 (fr) * 1991-05-07 1992-11-11 Merck & Co. Inc. Antagonistes des récepteurs fibrinogeniques
EP0565896A2 (fr) * 1992-04-13 1993-10-20 Hoechst Aktiengesellschaft Dérivés d'acide aspartique et leur préparation et utilisation
EP0578535A1 (fr) * 1992-06-30 1994-01-12 Adir Et Compagnie Nouveaux dérivés peptidiques actifs dans les processus d'adhesion cellulaire, leur procédé de préparation et les compositions pharmaceutiques qui les renferment
WO1994014775A1 (fr) * 1992-12-29 1994-07-07 Smithkline Beecham Corporation Composes inhibant l'aggregation des plaquettes
US5332726A (en) * 1989-09-29 1994-07-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic peptides and pseudopeptides
WO1994022907A1 (fr) * 1993-03-26 1994-10-13 Hoechst Aktiengesellschaft Nouveaux derives d'uree, leur preparation et leur utilisation
WO1994022835A2 (fr) * 1993-03-29 1994-10-13 Zeneca Limited Composes heterocycliques en tant qu'inhibiteurs de l'agregation plaquettaire
EP0725059A1 (fr) * 1993-10-19 1996-08-07 Sumitomo Pharmaceuticals Company, Limited Derive d'acide 2,3-diaminopropionique
WO1997024122A1 (fr) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Antagonistes du recepteur de vitronectine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553227A (en) * 1968-08-05 1971-01-05 Parke Davis & Co S-2-((2-(2-thiazolylcarbamoyl)ethyl)amino)ethyl thiosulfate, salts thereof, and methods for their production
US4684722A (en) * 1986-01-06 1987-08-04 E. R. Squibb & Sons, Inc. Monosulfactams

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0384362A2 (fr) * 1989-02-23 1990-08-29 F. Hoffmann-La Roche Ag Dérivés de la glycine
US5332726A (en) * 1989-09-29 1994-07-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic peptides and pseudopeptides
WO1991005562A1 (fr) * 1989-10-10 1991-05-02 Rorer International (Holdings), Inc. Peptides et pseudopeptides anti-thrombotiques
EP0512831A1 (fr) * 1991-05-07 1992-11-11 Merck & Co. Inc. Antagonistes des récepteurs fibrinogeniques
EP0565896A2 (fr) * 1992-04-13 1993-10-20 Hoechst Aktiengesellschaft Dérivés d'acide aspartique et leur préparation et utilisation
EP0578535A1 (fr) * 1992-06-30 1994-01-12 Adir Et Compagnie Nouveaux dérivés peptidiques actifs dans les processus d'adhesion cellulaire, leur procédé de préparation et les compositions pharmaceutiques qui les renferment
WO1994014775A1 (fr) * 1992-12-29 1994-07-07 Smithkline Beecham Corporation Composes inhibant l'aggregation des plaquettes
WO1994022907A1 (fr) * 1993-03-26 1994-10-13 Hoechst Aktiengesellschaft Nouveaux derives d'uree, leur preparation et leur utilisation
WO1994022835A2 (fr) * 1993-03-29 1994-10-13 Zeneca Limited Composes heterocycliques en tant qu'inhibiteurs de l'agregation plaquettaire
EP0725059A1 (fr) * 1993-10-19 1996-08-07 Sumitomo Pharmaceuticals Company, Limited Derive d'acide 2,3-diaminopropionique
WO1997024122A1 (fr) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Antagonistes du recepteur de vitronectine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9726250A1 *

Also Published As

Publication number Publication date
AU1699097A (en) 1997-08-11
WO1997026250A1 (fr) 1997-07-24
CA2242877A1 (fr) 1997-07-24
JP2000516197A (ja) 2000-12-05
AU713676B2 (en) 1999-12-09
EP0880511A1 (fr) 1998-12-02

Similar Documents

Publication Publication Date Title
EP1047425A4 (fr) Antagonistes du recepteur de l'integrine
EP0934305A4 (fr) Antagonistes de l'integrine
EP1100506A4 (fr) Antagonistes des recepteurs de l'integrine
EP1105389A4 (fr) Antagonistes de recepteurs d'integrine
EP1007051A4 (fr) Antagonistes du recepteur de l'integrine
CY2576B1 (en) Vitronectin receptor antagonists
EP0946164A4 (fr) Antagonistes de l'integrine
EP1007026A4 (fr) Antagonistes d'integrine
EP0880511A4 (fr) Antagonistes du recepteur integrine
HU9603525D0 (en) Vironectin receptor antagonists
EP0912175A4 (fr) Antagonistes du recepteur de fibrinogene
EP0763035A4 (fr) Antagonistes du recepteur de l'endotheline
IL130760A0 (en) Vitronectin receptor antagonists
EP0885205A4 (fr) Antagonistes des recepteurs de fibrinogenes
EP0885213A4 (fr) Antagonistes du recepteur du fibrinogene
IL135797A0 (en) Thrombin receptor antagonists
IL135028A0 (en) Vitronectin receptor antagonists
EP1027337A4 (fr) Antagonistes des recepteurs d'integrines
EP0929218A4 (fr) Antagonistes des recepteurs p2y
GB9820014D0 (en) Receptor antagonists and uses thereof
IL119820A0 (en) Integrin receptor antagonists
GB9603373D0 (en) Integrin receptor antagonists
ZA986930B (en) Integrin receptor antagonists
ZA9811500B (en) Integrin receptor antagonists
ZA9610690B (en) Integrin receptor antagonists.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990503

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 19990922

17Q First examination report despatched

Effective date: 20030731

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031211